Myers Scott Dunseth 4

What Happened

• Scott Dunseth, a member of Zentalis Pharmaceuticals' Board of Directors, received an award of 57,100 restricted stock units (RSUs) on June 16, 2026.
• The reported acquisition price is $0.00 (i.e., an equity award rather than a cash purchase); total cash consideration was $0. These RSUs represent a contingent right to receive one share of common stock per unit upon vesting.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing).
• Grant type/code: A (award/grant/acquisition) — 57,100 RSUs @ $0.00.
• Shares owned after transaction: not specified in the provided filing data.
• Footnote: RSUs granted under the Issuer's Non-Employee Director Compensation Program. Vesting occurs on the earlier of (a) June 16, 2027 or (b) the next annual meeting of stockholders, subject to continued board service through the vesting date.
• Exhibit included: Exhibit 24 (Power of Attorney).

Context

• RSU awards are a form of compensation for board service and are not a market purchase or sale; they vest in the future if service conditions are met.
• Because this is an award (not a buy or sell), it should be interpreted as compensation-related, not a direct signal of the director buying or selling shares on the open market.